December 4, 2012
Although Vertex (Nasdaq: VRTX ) is still up 20% for the year as a whole, it dropped by about a fifth of its share price in November. The stock has been hit twofold. Results keep pouring in from both Abbott Labs' (NYSE: ABT ) and Gilead's (Nasdaq: GILD ) next generation hepatitis-C drug cocktails, with tremendous cure rates and without requiring the use of interferon -- you start to see the problem for Vertex's Incivek. Furthermore, quarterly results had sales of its cystic fibrosis drug coming in light of estimates, but international expansion should accelerate its growth. Watch and find out what David Williamson thinks about Vertex's month and what the future holds for the stock.
With the impending spinoff of its branded-drug business, Abbott Labs is losing a massive blockbuster drug in Humira. It's a confusing event to understand, with many investors left wondering what to do with these two stocks once they're separated. To help investors better understand the upcoming event, the Fool has created a brand new premium report outlining both Abbott Labs and its spinoff, AbbVie. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this 2-for-1 report by clicking here now.